Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V. Heppt, Carola Berking, Felix Kiecker et al.|European Journal of Cancer|2017Cited by 203
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Lisa Zimmer, Felix Kiecker et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 88
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisMarkus V. Heppt, Carola Berking, Thomas Eigentler et al.|Cancer Immunology Immunotherapy|2016Cited by 81
CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature reviewSvenja Vanessa Wiedemann, Maria Rita Gaiser, Verena Müller et al.|EJC Skin Cancer|2023Cited by 5
Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibitionMarkus V. Heppt, Carola Berking, Lucie Heinzerling et al.|Journal Der Deutschen Dermatologischen Gesellschaft|2017Cited by 0